MedTrace Logo

A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

NCT06821334 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-02-12

No results posted yet for this study

Summary

The goal of this study is to learn how safe MK-6194 is in healthy Chinese adults and how well people tolerate it.

Conditions

  • Healthy

Interventions

BIOLOGICAL

MK-6194

Subcutaneous Administration

BIOLOGICAL

Placebo

Subcutaneous administration

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-23
Primary Completion
2024-08-09
Completion
2024-08-09
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06821334 on ClinicalTrials.gov